Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.46 |
| ▸ | JAK1 | P23458 | 11/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301441 | 0.76 | JAK2 (0.46) | JAK2JAK1EGLN2JAK3IKBKB | |
| SCHEMBL3301440 | 0.76 | JAK2 (0.46) | JAK2JAK1EGLN2JAK3IKBKB | |
| SCHEMBL2772600 | 0.75 | MAP3K5 (0.61) | JAK2JAK1AHRTTK | |
| SCHEMBL3300667 | 0.74 | AHR (0.39) | JAK2EGLN2JAK3AHR | |
| SCHEMBL19762846 | 0.74 | JAK1 (0.40) | JAK1LCKGSK3B | |
| SCHEMBL4040564 | 0.74 | LCK (0.42) | LCKBRD9 | |
| SCHEMBL45724 | 0.74 | JAK1 (0.69) | JAK2JAK1JAK3IKBKBRIPK2 | |
| SCHEMBL29786519 | 0.73 | ROCK2 (0.43) | LCKAHRBRD9TTK | |
| SCHEMBL16439318 | 0.73 | AHR (0.50) | JAK2JAK1EGLN2JAK3IKBKB | |
| SCHEMBL2789479 | 0.72 | JAK1 (0.59) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368161-A1 | CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF | CGENETECH (SUZHOU,CHINA) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4446322-A1 | CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023138550-A1 | CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF | 盛世泰科生物医药技术(苏州)有限公司 | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368161-A1 | CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF | MCL1, BCL9, BCL9L | JAK2 516/4885JAK1 2434/4885EGLN2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.